乳腺癌治疗的个性化有利于将新的分子靶向疗法引入临床实践。其中，细胞周期蛋白依赖性激酶4和6（CDK4/6）抑制剂变得越来越重要，近年来palbociclib、ribociclib和abemaciclib与内分泌治疗联合用药获得批准。目前，尚无指南可用于监测和管理与使用这些药物相关的潜在长期毒性。由欧洲肿瘤学家组成的多学科小组在药理学家、血液学家、肝病学家和肺病学家的支持下，根据文献综述和临床经验讨论长期毒性的管理。该小组提供了详细的路线图来管理与临床实践中使用 CDK4/6 抑制剂相关的长期毒性。了解与每种 CDK4/6 抑制剂相关的毒性特征的频率和特征对于决策过程非常重要，以便将正确的药物与正确的患者相匹配。版权所有 © 2023 Cazzaniga, Ciaccio, Danesi, Duhoux, Girmenia, Zaman, Lindman 、Luppi、Mavroudis、Paris、Olubuukola、Samreen、Schem、Singer 和 Snegovoy。

The personalization of therapies in breast cancer has favoured the introduction of new molecular-targeted therapies into clinical practice. Among them, cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have acquired increasing importance, with the approval in recent years of palbociclib, ribociclib, and abemaciclib in combination with endocrine therapy. Currently, no guidelines are available to monitor and manage potential long-term toxicities associated with the use of these drugs. A multidisciplinary panel of European oncologists, was supported by a pharmacologist, a hematologist, a hepatologist and a pulmonologist to discuss the management of long-term toxicities, based on the literature review and their clinical experience. The panel provided detailed roadmaps to manage long-term toxicities associated with the use of CDK4/6 inhibitors in clinical practice. Knowing the frequency and characteristics of the toxicity profile associated with each CDK4/6 inhibitor is important in the decision-making process to match the right drug to the right patient.Copyright © 2023 Cazzaniga, Ciaccio, Danesi, Duhoux, Girmenia, Zaman, Lindman, Luppi, Mavroudis, Paris, Olubukola, Samreen, Schem, Singer and Snegovoy.